Assessing the feasibility of conducting and using health technology assessment in Colombia: The case of severe haemophilia A
暂无分享,去创建一个
[1] A. Briggs,et al. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. , 2002, Health economics.
[2] D. Eddy. Clinical decision making: from theory to practice. Anatomy of a decision. , 1990, JAMA.
[3] H. M. van den Berg,et al. A survey of adherence to haemophilia therapy in six European countries: results and recommendations , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] P. Babyn,et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study , 2006, Journal of thrombosis and haemostasis : JTH.
[5] Carol Grbich,et al. Qualitative Research in Health: An Introduction , 1999 .
[6] Pierre Pluye,et al. Understanding divergence of quantitative and qualitative data (or results) in mixed methods studies , 2009 .
[7] N. Britten. Qualitative Research: Qualitative interviews in medical research , 1995 .
[8] R. Ljung,et al. Factor VIII products and inhibitor development in severe hemophilia A. , 2013, The New England journal of medicine.
[9] A. Iorio,et al. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2006, The Cochrane database of systematic reviews.
[10] A. Farrugia,et al. Health technology assessment and haemophilia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.
[11] L. Mantovani,et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.
[12] R. Carter,et al. Health technology assessment: reflections from the Antipodes. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] M. Goetghebeur,et al. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa , 2012, Cost Effectiveness and Resource Allocation.
[14] K. Fischer,et al. Treatment for life for severe haemophilia A– A cost‐utility model for prophylaxis vs. on‐demand treatment , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[15] S. Simoens. Use of Economic Evaluation in Decision Making , 2010, Drugs.
[16] A S Detsky,et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[17] G. Batty,et al. The advantages of being called NICE: a systematic review of journal article titles using the acronym for the National Institute for Health and Clinical Excellence. , 2008, Journal of public health.
[18] C. Pashos,et al. Health technology assessment: lessons learned from around the world--an overview. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[19] C. Deal,et al. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients , 2010, Cost effectiveness and resource allocation : C/E.
[20] R. Tedder,et al. Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. , 1993, Blood.
[21] B. Evatt,et al. The tragic history of AIDS in the hemophilia population, 1982–1984 , 2006, Journal of thrombosis and haemostasis : JTH.
[22] K. Charmaz,et al. Constructing Grounded Theory: A practical guide through qualitative analysis Kathy Charmaz Constructing Grounded Theory: A practical guide through qualitative analysis Sage 224 £19.99 0761973532 0761973532 [Formula: see text]. , 2006, Nurse researcher.
[23] Lydia Kapiriri,et al. Setting priorities for health interventions in developing countries: a review of empirical studies , 2009, Tropical medicine & international health : TM & IH.
[24] Murray D. Krahn,et al. INTRODUCTION TO HEALTH TECHNOLOGY ASSESSMENT , 2014 .
[25] S. Homan,et al. Determining Transition Probabilities , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.
[26] Karl Claxton,et al. Assessing Quality in Decision Analytic Cost-Effectiveness Models , 2000, PharmacoEconomics.
[27] K. Fischer,et al. Comparing outcomes of different treatment regimens for severe haemophilia , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[28] S. Oliver,et al. Involving consumers in a needs‐led research programme: a pilot project , 2001, Health expectations : an international journal of public participation in health care and health policy.
[29] A Laupacis,et al. The effect of elective total hip replacement on health-related quality of life. , 1993, The Journal of bone and joint surgery. American volume.
[30] P. Mannucci,et al. AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider , 2003, Journal of thrombosis and haemostasis : JTH.
[31] Edward G. D. Tuddenham,et al. Erratum: The hemophilias - From royal genes to gene therapy (New England Journal of Medicine (June 7, 2001) 344 (1773-9)) , 2001 .
[32] Montse Moharra,et al. Addressing issues in health technology assessment promotion: Motives, enablers, and barriers , 2011, International Journal of Technology Assessment in Health Care.
[33] P. Shekelle,et al. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? , 2001, JAMA.
[34] K. Kurnik,et al. Identification and long‐term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.
[35] Jon Sussex,et al. Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold , 2013 .
[36] Donald G. Saari,et al. Mathematical Structure of Voting Paradoxes: II. Positional Voting , 1999 .
[37] J Hjelmgren,et al. Health economic guidelines--similarities, differences and some implications. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[38] K. Amfo. Health technology assessment. , 1996, World health forum.
[39] L. Garrison,et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[40] A. Diederich,et al. Age as a Criterion for Setting Priorities in Health Care? A Survey of the German Public View , 2011, PloS one.
[41] J. Kirk,et al. Reliability and Validity in Qualitative Research , 1985 .
[42] G. Auerswald,et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[43] J. Aznar,et al. Results of an orthopaedic survey in young patients with severe haemophilia in Spain , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[44] K. Fischer,et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[45] A Gafni,et al. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? , 1992, Journal of health economics.
[46] Anselm L. Strauss,et al. Awareness of Dying , 1966 .
[47] P. Giangrande. Blood Products for Hemophilia , 2012, BioDrugs.
[48] Paul Kind,et al. From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking , 2012, Cost Effectiveness and Resource Allocation.
[49] David Hailey,et al. TOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT , 2003, International Journal of Technology Assessment in Health Care.
[50] A. Gafni,et al. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. , 1993, Journal of health economics.
[51] M. Ezzati,et al. [Priority setting for health interventions in Mexico's System of Social Protection in Health]. , 2007, Salud publica de Mexico.
[52] Ingrid M. Nembhard,et al. Qualitative and Mixed Methods Provide Unique Contributions to Outcomes Research , 2009, Circulation.
[53] J. Gill,et al. Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.
[54] K. Chalkidou,et al. Priority-setting institutions in health: recommendations from a center for global development working group. , 2012, Global heart.
[55] C. Mitton,et al. Cost effectiveness analysis in health care: contraindications , 2002, BMJ : British Medical Journal.
[56] Aris Angelis,et al. Multiple criteria decision analysis for valuebased assessment of new medical technologies:a conceptual framework , 2013 .
[57] H. A. Lingstone,et al. The Delphi Method: Techniques and Applications , 1976 .
[58] Graham Loomes,et al. Valuing Life Years and QALYs: Transferability and Convertability of Values Across the UK Public Sector , 2002 .
[59] Derek J. Pike,et al. Empirical Model‐building and Response Surfaces. , 1988 .
[60] C. Lindblom. THE SCIENCE OF MUDDLING THROUGH , 1959 .
[61] Staffan Larsson. Life expectancy of Swedish haemophiliacs, 1831–1980 , 1985, British journal of haematology.
[62] R. Ljung,et al. Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[63] Michael E. Chernew,et al. Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[64] A. Strauss,et al. The discovery of grounded theory: strategies for qualitative research aldine de gruyter , 1968 .
[65] Paul Kind,et al. WHICH CRITERIA ARE CONSIDERED IN HEALTHCARE DECISIONS? INSIGHTS FROM AN INTERNATIONAL SURVEY OF POLICY AND CLINICAL DECISION MAKERS , 2013, International Journal of Technology Assessment in Health Care.
[66] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[67] Mandy Ryan,et al. Using discrete choice experiments to value health and health care , 2008 .
[68] J. Lusher,et al. Factor VIII inhibitors with recombinant products : prospective clinical trials. Discussion , 2000 .
[69] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[70] J Chilcott,et al. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. , 2010, Health technology assessment.
[71] R. Ljung. The risk associated with indwelling catheters in children with haemophilia , 2007, British journal of haematology.
[72] Giuseppe Barletta,et al. Introduction to health technology assessment , 2012 .
[73] C. Pope,et al. Assessing quality in qualitative research , 2000, BMJ : British Medical Journal.
[74] D. Grobbee,et al. Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[75] Ricardo Sánchez Pedraza,et al. Metodología de calificación y resumen de las opiniones dentro de consensos formales , 2009 .
[76] L. Erickson,et al. Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications , 2008, BMC health services research.
[77] G. Wilensky. Developing A Center For Comparative Effectiveness , 2006 .
[78] A. Miners,et al. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[79] E. Nord. Health Status Index Models for Use in Resource Allocation Decisions: A Critical Review in the Light of Observed Preferences for Social Choice , 1996, International Journal of Technology Assessment in Health Care.
[80] A. Schutz. On Phenomenology And Social Relations , 1970 .
[81] J. Levy,et al. AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations. , 1986, Blood.
[82] Sean D Sullivan,et al. Health technology assessment for resource allocation decisions: Are key principles relevant for Latin America? , 2010, International Journal of Technology Assessment in Health Care.
[83] J. Dolan. Multi-Criteria Clinical Decision Support , 2010, The patient.
[84] E. Santagostino,et al. Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A , 2011, ClinicoEconomics and outcomes research : CEOR.
[85] Mark Sculpher,et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[86] J. Caro,et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[87] S. Teutsch,et al. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. , 1996, The Journal of pediatrics.
[88] M. Franchini,et al. The management of hemophilia in elderly patients , 2007, Clinical interventions in aging.
[89] D. Grobbee,et al. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.
[90] G. Higginbottom. Sampling issues in qualitative research. , 2004, Nurse researcher.
[91] M J Buxton,et al. Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.
[92] C. Murray,et al. Household catastrophic health expenditure: a multicountry analysis , 2003, The Lancet.
[93] Anthony J Culyer,et al. National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.
[94] C. Sabin,et al. Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia , 2012, PharmacoEconomics.
[95] S. Paisley,et al. Economic modelling of different treatment strategies for haemophilia A with high‐responding inhibitors , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[96] H. Leufkens,et al. Differences in Attitudes, Knowledge and Use of Economic Evaluations in Decision-Making in The Netherlands , 2000, PharmacoEconomics.
[97] M. Hilgartner. Current treatment of hemophilic arthropathy , 2002, Current opinion in pediatrics.
[98] D. Eddy. Evidence-based medicine: a unified approach. , 2005, Health affairs.
[99] G. Carrasquilla,et al. Equidad en la Deteccin del Cncer de Seno en Colombia , 2008 .
[100] C. Ham,et al. Reasonable Rationing: international experience of priority setting in health care , 2003 .
[101] P. Petrini. Identifying and overcoming barriers to prophylaxis in the management of haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.
[102] K. Fischer,et al. Prophylaxis for severe haemophilia: clinical and economical issues , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[103] M Johannesson,et al. On the decision rules of cost-effectiveness analysis. , 1993, Journal of health economics.
[104] W. Gerth,et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[105] D. Grobbee,et al. RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.
[106] A. Gafni,et al. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. , 2002, Health economics.
[107] J. Astermark,et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[108] M. Drummond,et al. Nasty or nice? A perspective on the use of health technology assessment in the United Kingdom. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[109] M. Recht,et al. Current Options and New Developments in the Treatment of Haemophilia , 2011, Drugs.
[110] B. Glaser. Basics of Grounded Theory Analysis: Emergence Vs. Forcing , 1992 .
[111] C. Hausl,et al. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors , 2007, British journal of haematology.
[112] L. Prihodova,et al. A survey of the outcome of prophylaxis, on‐demand or combined treatment in 20–35 year old men with severe haemophilia in four European countries , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.
[113] Hanane Khoury,et al. Bridging Health Technology Assessment (HTA) and Efficient Health Care Decision Making with Multicriteria Decision Analysis (MCDA) , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[114] J. Maahs,et al. Practice patterns in haemophilia A therapy – global progress towards optimal care , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.
[115] Patrick A Crookes,et al. Research Into Practice: Essential Skills for Reading and Applying Research in Nursing and Health Care , 1998 .
[116] J. Mchardy,et al. Twice weekly prophylactic therapy in haemophilia A. , 1977, Journal of clinical pathology.
[117] Christine A. Lee,et al. The best of times, the worst of times , 2001 .
[118] J. Stockman. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .
[119] M. Mcgregor,et al. Assessing the Impact of Health Technology Assessment , 1997, International Journal of Technology Assessment in Health Care.
[120] E. Murphy,et al. Qualitative research methods in health technology assessment: a review of the literature. , 1998, Health technology assessment.
[121] Norbert Schwarz,et al. Misimagining the unimaginable: the disability paradox and health care decision making. , 2005, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[122] J. Kendall,et al. Sibling accounts of attention deficit hyperactivity disorder (ADHD). , 1999, Family process.
[123] P. Mannucci,et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[124] M. Drummond,et al. IMPLEMENTING THE FINDINGS OF HEALTH TECHNOLOGY ASSESSMENTS , 2000, International Journal of Technology Assessment in Health Care.
[125] G Loomes,et al. Visual Analog Scales, Standard Gambles, and Relative Risk Aversion , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.
[126] R. Baltussen,et al. Priority setting of health interventions: the need for multi-criteria decision analysis , 2006, Cost effectiveness and resource allocation : C/E.
[127] Christopher McCabe,et al. Health Technology Funding Decision-Making Processes Around the World , 2011, PharmacoEconomics.
[128] Anselm L. Strauss,et al. Awareness of Dying , 1966 .
[129] Douglas K. Martin,et al. Accountable priority setting for trust in health systems - the need for research into a new approach for strengthening sustainable health action in developing countries , 2009, Health research policy and systems.
[130] L. Valentino,et al. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[131] V. Blanchette,et al. Cost‐utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on‐demand therapy in young children with severe haemophilia A , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[132] D. Feeny,et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. , 1996, Medical care.
[133] M. Mcgregor. Can our health services be saved by technology evaluation? The Quebec experience. , 1994, Clinical and investigative medicine. Medecine clinique et experimentale.
[134] F. Mandelli,et al. Evaluation of prophylactic replacement therapy in haemophilia B. , 2009, Scandinavian journal of haematology.
[135] J. Oldenburg,et al. Haemophilia care then, now and in the future , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.
[136] M. Hammersley. What's Wrong With Ethnography? , 1991 .
[137] P. Taylor. Clinical Decision Making: From Theory to Practice , 1996 .
[138] J. Ingerslev,et al. Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in Lithuania , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[139] M. Johannesson. The Australian Guidelines for Subsidisation of Pharmaceuticals , 1992, PharmacoEconomics.
[140] R. Engelbert,et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score , 2011, Arthritis care & research.
[141] Lisa A Bero,et al. "Developing good taste in evidence": facilitators of and hindrances to evidence-informed health policymaking in state government. , 2008, The Milbank quarterly.
[142] D. Czepa,et al. Cross sectional study to investigate the influence of treatment regimes on the development of haemophilic arthropathy. , 2009, Hamostaseologie.
[143] M. Rawlins. In pursuit of quality: the National Institute for Clinical Excellence , 1999, The Lancet.
[144] J. Mamikhani,et al. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran , 2009, International Journal of Technology Assessment in Health Care.
[145] Scharrer,et al. Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.
[146] M. Drummond,et al. Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .
[147] H. Pettersson,et al. Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.
[148] E. Berntorp. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.
[149] P. Rosenau. Managing Medical Technology: Lessons for the United States from Quebec and France , 2000, International journal of health services : planning, administration, evaluation.
[150] V. Braun,et al. Using thematic analysis in psychology , 2006 .
[151] Frank A. Sloan,et al. Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .
[152] C. Casas,et al. The History and Evolution of the Clinical Effectiveness of Haemophilia Type A Treatment: A Systematic Review , 2014, Indian Journal of Hematology and Blood Transfusion.
[153] V. Jiménez‐Yuste,et al. Is on‐demand treatment effective in patients with severe haemophilia? , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.
[154] A. Coppola,et al. Primary prophylaxis in children with haemophilia. , 2008, Blood transfusion = Trasfusione del sangue.
[155] J. Aznar,et al. The orthopaedic status of severe haemophiliacs in Spain , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.